In sub-Saharan Africa, however, about 43 percent of people are at risk for the disease. They do not have access to mosquito protection such as bed nets or bug sprays. Being the continent with the highest number of malaria cases, the new vaccine called the Mosquirix will be tested in Kenya, Ghana and Malawi beginning next year.
Ghana, Kenya and Malawi will pilot the world’s first malaria vaccine from 2018 – The injectable vaccine which is known as “Mosquirix” will be offered to babies and children in high-risk areas as part of real-life trials – The vaccines developed by GlaxoSmithKline (GSK) is to protect children from the most deadly form of malaria in Africa . The WHO said the vaccines was developed by British drugproducer GlaxoSmithKline (GSK) to protect children from the most deadly form of malaria in Africa.
BBC News reported that it is not clear how feasible the vaccine is to use in the poorest parts of the world. It is said to be given four times to get its full effects: once a month for three months, then another dose 18 months after. While the malaria vaccine was developed in tightly controlled and well-funded clinical trials, it is not clear whether or not it can be as effective in the “real world” where there is limited access to health care.
Global efforts in the last 15 years cut the malaria death toll by 62 per cent between 2000 and 2015. The WHO pilot programme will assess whether the Mosquirix’s protective effect in children aged five to 17 months can be replicated in real-life. It will also assess the feasibility of delivering the four doses needed, and explore the vaccine’s potential role in reducing the number of children killed by the disease. The WHO said Malawi, Kenya and Ghana were chosen for the pilot due to several factors, including having high rates of malaria as well as good malaria programmes, wide use of bed-nets, and well-functioning immunisation programmes. The UN organisation said each of the three countries will decide on the districts and regions to be included in the pilots. It also said high malaria areas will get priority since these are where experts expect to see most benefit from the use of the vaccine “Mosquirix” was developed by GSK in partnership with the non-profit PATH Malaria Vaccine Initiative and part-funded by the Bill & Melinda Gates Foundation..
See the video below :